Shares of Iridex Corporation (IRIX Quick QuoteIRIX - Free Report) have declined 23.8% since the company reported its earnings for the quarter ended Jan. 3, 2026, underperforming the S&P 500 index’s 3.9% decline over the same period. Over the past month, the stock has fallen 28.4%, compared with the S&P 500’s 8% drop, reflecting notably weaker performance relative to the broader market.

Iridex incurred a fourth-quarter 2025 net loss of 1 cent per share, narrower than a net loss of 5 cents per share in the prior-year period.

Revenue of $14.7 million denoted a 16% year-over-year rise from $12.7 million, driven primarily by higher retina system sales and glaucoma probe demand. 

Gross profit for the quarter was $5.5 million, or a 37% margin compared with $5.6 million, or a 44% margin, in the year-ago period. 

Net loss narrowed significantly to $0.2 million from a loss of $0.8 million in the prior-year period.

Iridex Corporation Price, Consensus and EPS Surprise

Iridex Corporation price-consensus-eps-surprise-chart | Iridex Corporation Quote

Segment Performance and Key Metrics

Growth was broad-based across Iridex’s core product categories. Retina product revenue increased 22% year over year in the fourth quarter to $8.9 million, supported by higher sales of Pascal systems and other retina offerings. Meanwhile, revenue from the Cyclo G6 glaucoma product family rose 15% to $3.8 million, driven by higher probe utilization.

Operational metrics also showed improvement. The company sold 15,900 Cyclo G6 probes in the quarter, up from 13,300 a year earlier, although system sales dipped slightly to 44 units from 47. Gross margin declined to 37% from 44%, reflecting higher manufacturing costs, tariff-related pressures and lower overhead absorption due to reduced inventory levels.

Management Commentary

Management characterized 2025 as a “transformational year,” highlighting revenue growth, cost reductions and the achievement of positive adjusted EBITDA for the first time in recent history. CEO Patrick Mercer emphasized that operational streamlining and expense controls have repositioned the company toward sustainable profitability and positive cash flow generation.

Leadership also pointed to continued momentum across both glaucoma and retina businesses, supported by an expanding installed base and improved commercial execution. Management expressed confidence that these factors, combined with ongoing efficiency initiatives, will support further progress in 2026.

Drivers of Performance

Revenue growth was primarily driven by higher retina system sales, particularly Pascal, along with increased glaucoma probe utilization and an additional selling week in the fiscal quarter. Commercial initiatives, including targeted physician engagement and pricing improvements, also contributed to glaucoma revenue gains. 

However, profitability remained pressured by external and operational factors. Gross margin contraction stemmed from increased manufacturing costs, tariff developments and inventory-related dynamics. Additionally, macroeconomic and geopolitical challenges weighed on certain regions.

Management noted that the conflict in the Middle East has materially affected sales in that geography, while tariff uncertainty in China and currency pressures in Japan impacted performance in Asia.

2025 Update

For the full year, revenues rose 8% to $52.7 million. Gross profit was $19.2 million with a 37% margin, compared to $19.5 million and a 40% margin in 2024.

Net loss improved to $4.4 million, or 26 cents per share, from $8.9 million, or 54 cents per share, in 2024.

Guidance and Outlook

For 2026, Iridex expects revenue in the range of $51 million to $53 million. This outlook assumes no contribution from the Middle East due to ongoing geopolitical disruptions. On a comparable basis, excluding that region, the guidance implies growth of 1% to 5% over 2025.

The company anticipates adjusted operating expenses of $19 million to $19.5 million and expects to generate positive operating cash flow for the full year. Management reiterated that cost reductions, manufacturing transitions and commercial execution are expected to support margin improvement over time.

Other Developments

Iridex continued executing restructuring and cost optimization initiatives during the quarter. These include relocating certain general and administrative functions out of California, expected to generate quarterly savings beginning in early 2026, and plans to relocate the headquarters later in the year to further reduce fixed costs.

The company is also advancing a multiyear transition toward third-party contract manufacturing, which is expected to lower the cost of goods and support margin expansion, with meaningful progress anticipated in 2026 and full implementation by 2027.